Study Summary
This trial will explore if combining radiation with durvalumab, carboplatin and etoposide can help treat extensive-stage small cell lung cancer. Participation lasts 48 months.
- Small Cell Lung Cancer
- Lung Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: 48 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Participants With Extensive Small Cell Lung Cancer (All Participants)
1 of 1
Experimental Treatment
49 Total Participants · 1 Treatment Group
Primary Treatment: Participants With Extensive Small Cell Lung Cancer (All Participants) · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is enrollment for the trial still open?
"As per the information on clinicaltrials.gov, this research is looking for volunteers and has been in operation since August 19th of 2022 with a recent update occurring on February 14th 2023." - Anonymous Online Contributor
Has the application for Participants With Extensive Small Cell Lung Cancer (All Participants) been accepted by the FDA?
"Our collective sentiment at Power is that Participants With Extensive Small Cell Lung Cancer (All Participants) have the safety rating of 2, as it has been tested in Phase 2 clinical trials and only preliminary evidence for its efficacy exists." - Anonymous Online Contributor
Have any experiments been conducted that included patients diagnosed with extensive small cell lung cancer?
"At present, 1091 clinical trials for Participants With Extensive Small Cell Lung Cancer (All Participants) are live with 293 of those trials in the most advanced phase. Although a number of these studies can be located in Orlando, Florida, there is an expansive network of 58978 research centres researching this disease across the world." - Anonymous Online Contributor
What health concerns can be addressed by Participants With Extensive Small Cell Lung Cancer (All Participants)?
"Patients with Extensive Small Cell Lung Cancer (All Participants) often receive this medication to address recurrent cancers. It is also used off-label for advanced cervical cancer, gestational trophoblastic disease and other medical concerns." - Anonymous Online Contributor
What is the current enrollment number for this clinical trial?
"Affirmative. Clinicaltrials.gov attests that this research study, which was initially posted on August 19th 2022, is presently recruiting individuals for participation. 49 people are needed to be enrolled from a solitary medical location." - Anonymous Online Contributor